Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22494209 | 0.77 | AKR1B1 (0.35) | AKR1B1 | |
| SCHEMBL27393122 | 0.76 | AKR1B1 (0.37) | ALDH1A1AKR1B1CYP3A4CYP2C9HPGD | |
| SCHEMBL27390402 | 0.76 | MEN1 (0.44) | AKR1B1CYP3A4CYP2C9HSD11B1MEN1 | |
| SCHEMBL475089 | 0.74 | ALDH1A1 (0.55) | MAPTKDM4EL3MBTL1ALDH1A1HTT | |
| SCHEMBL29468592 | 0.74 | ALDH1A1 (0.55) | MAPTKDM4EL3MBTL1ALDH1A1HTT | |
| SCHEMBL21753445 | 0.74 | HTR2A (0.38) | MAPTKDM4EALDH1A1AKR1B1HPGD | |
| SCHEMBL4540142 | 0.74 | AKR1B1 (0.58) | ALDH1A1AKR1B1SMN1; SMN2 | |
| SCHEMBL27529895 | 0.73 | AKR1B1 (0.64) | AKR1B1KMT2A | |
| SCHEMBL28830409 | 0.72 | KDM4E (0.45) | MAPTKDM4EL3MBTL1ALDH1A1HTT | |
| SCHEMBL8782170 | 0.72 | RAPGEF4 (0.49) | L3MBTL1ALDH1A1HTTAKR1B1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257539-B1 | AMINO PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2004-12-29 | — | — | EP | disclosed |
| US-6531478-B2 | For therapy of eating disorder, obesity, bulimia nervosa, diabetes, binge eating, anorexia nervosa, dyslipidimia, hypertension, memory loss, epileptic seizures, migraine, sleep disturbances, pain, sexual/reproductive disorders | KORDIK CHERYL P (US) | 2003-03-11 | — | — | US | disclosed |
| EP-1257539-A2 | AMINO PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF OBESITY AND OTHER DISORDERS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020065289-A1 | Amino pyrazole derivatives useful for the treatment of obesity and other disorders | KORDIK CHERYL P (US) | 2002-05-30 | — | — | US | disclosed |
| WO-2001062737-A2 | AMINO PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065289-A1 | Amino pyrazole derivatives useful for the treatment of obesity and other disorders | NPY5R, NPY1R, NPY4R | MAPT 2451/4885KDM4E 2084/4885L3MBTL1 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.